hrp0082p1-d3-128 | Fat Metabolism & Obesity (2) | ESPE2014

Acylated and Unacylated Ghrelin Levels in Children and Young Adults with Prader–Willi Syndrome

Kuppens Renske , Diene Gwenaelle , Bakker Nienke , Molinas Catherine , Faye S , Nicolino Marc , Bernoux Delphine , Delhanty Patric , Jan van der Lelij Aart , Allas Soraya , Julien Michiel , Delale Thomas , Tauber Maithe , Hokken-Koelega Anita

Background: Prader–Willi syndrome (PWS) is characterized by a switch in early childhood from failure to thrive to excessive weight gain and hyperphagia with impaired satiety. The underlying mechanism for this switch may involve hyperghrelinemia, but only poor data exists regarding levels of acylated ghrelin (AG), unacylated ghrelin (UAG), and the AG/UAG ratio in PWS.Objective and hypotheses: To investigate plasma levels of AG and UAG in PWS, compare...

hrp0094s3.2 | Management of Rare Obesity | ESPE2021

Hypothalamic Obesity in Craniopharyngioma

Muller Hermann L. ,

Although craniopharyngiomas are of low-grade histological dignity and have good prognosis in terms of overall survival, survivors may suffer from devastating consequences caused by hypothalamic damage. Disease and/or treatment-related hypothalamic damage leads to disturbed hunger-satiety and thirst feelings, decreased energy expenditure, behavioral problems, disturbances of circadian rhythm, temperature dysregulation, and pituitary dysfunction. These patients are at great risk...

hrp0094p2-326 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Differential diagnosis of pre- and postnatal short stature revisited: 3-M syndrome

Karatsiolis Platonas , Kamrath Clemens , Rakicioglu Hande , Wudy Stefan ,

Introduction: The 3 M- syndrome is a rare autosomal recessive disease, which was named after the three first authors Miller, McKusick and Malvaux. It is characterized by pre- and postnatal disproportionate short stature with micromelia, relative macrocephaly, and radiological bone dysmorphism. It is based on a mutation in one of the three genes CUL7, OBSL1 or CCDC8.Methodology: We report on a meanwhile 4 4/12- year- old girl who presente...

hrp0089p1-p119 | Fat, Metabolism and Obesity P1 | ESPE2018

Telemedicine Therapy for Overweight Adolescents: First Results of a Novel Smartphone App Intervention Using a Behavioural Health Platform

Heldt Katrin , Buchter Dirk , Brogle Bjorn , Chen-Hsuan Iris Shih , Ruegger Dominik , Filler Andreas , Gindrat Pauline , Durrer Dominique , Farpour-Lambert Nathalie , Kowatsch Tobias , l'Allemand Dagmar

Introduction: Despite improved therapy measures since 2014 the prevalence of overweight and obesity in Swiss adolescence stabilized on 19%. Particular challenges are lack of adherence to therapy in youth who are in difficult life situations or live further from specified centres. Therefore it is essential to find simple and novel therapeutic approaches. But although the number of digital based health information systems increases steadily, the effectiveness in reaching long te...

hrp0095p2-264 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

StAR gene mutation : description of puberty development and genital life from 6 patients 46,XX with classic Congenital Lipoid Adrenal Hyperplasia.

Jardin-Millet Isabelle , Amouroux Cyril , Dufourg Marie-Noelle , Lambert Anne-Sophie , Bouvattier Claire , Parada-Bonte Fabienne , Reynaud Rachel , Demeinex Estelle , Courbiere Blandine , Albarel FrÉDÉRique , Netchine IrÈNe , Houang Muriel

Introduction: Congenital Lipoid Adrenal Hyperplasia (CLAH) is a severe deficiency of adrenal and gonadal steroidogenesis, caused by mutations in the StAR gene and the accumulation of cholesterol in the outer mitochondrial membrane due to steroidogenic acute regulatory protein (StAR) deficiency. Affected patients present peripheral adrenal insufficiency with early onset, and variable phenotypes at the age of puberty.Objective of o...

hrp0089p2-p135 | Fat, Metabolism and Obesity P2 | ESPE2018

A Simple Relaxation Exercise Reduces Stress in Obese Youth - A Path to a Healthy Lifestyle?

Stasinaki Aikaterini , Buchter Dirk , Shih C.-H. I. , Heldt Katrin , White Catherine , Ruegger Dominic , Filler Andreas , Gindrat Pauline , Durrer Dominique , Brogle Bjorn , Farpour-Lambert Nathalie , Kowatsch Tobias , L'Allemand Dagmar

Introduction: Lack of impulse control and impaired stress regulation may explain the development of obesity and its challenging therapy, already in youth. To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services implemented in a novel Smartphone App supported intervention have effects on stress and weight outcomes.Method...

hrp0086p1-p618 | Growth P1 | ESPE2016

Design and Clinical Development of TransCon Growth Hormone for Growth Hormone Deficiency (GHD)

Beckert Michael , Gilfoyle David , Mikkelsen Jan Moller , Rasmussen Grethe , Rau Harald , Sprogoe Kennett

Background: TransCon GH is designed as a once-weekly sustained-release prodrug of recombinant human GH (hGH, somatropin). Based on the inert TransCon prodrug technology unmodified native hGH is released with a Cmax and AUC comparable to daily therapy. TransCon GH leverages the known pharmacology of daily hGH and is being developed for the treatment of GH deficiency (GHD) in children and adults.Objective and hypotheses: Develop a safe and efficacious sust...

hrp0084wg4.2 | Obesity | ESPE2015

A Monomeric Peptide Triagonist for the Treatment of Obesity and Diabetes

Clemmensen Christoffer , Finan Brian , Muller Timo , DiMarchi Richard , Tschop Matthias

Encouraged by unimolecular dual incretin co-agonists (GLP1/GIP) to enhance glycemic efficacy (Finan et al. 2013, Sci Transl Med) and GLP1/glucagon co-agonists to enhance weight loss efficacy (Day et al. 2009, Nat Chem Biol) and to restore diet-induced leptin sensitivity (Clemmensen et al. 2014, Diabetes), we recently developed the first tri-agonist (GLP1/GIP/glucagon) for the treatment of metabolic disorders (Finan et al. 2014, Nat Med). Importantly, this concerted triple agon...

hrp0084p2-389 | Fat | ESPE2015

Childhood Craniopharyngioma with Hypothalamic Obesity – No Long-term Weight Reduction due to Rehabilitation Programs

Sterkenburg Anthe S , Hoffmann Anika , Gebhardt Ursel , Muller Hermann L

Background: Severe obesity due to hypothalamic involvement has major impact on prognosis in long-term survivors of childhood-onset craniopharyngioma. The long-term effects of rehabilitation efforts on weight development and obesity in these patients are not analysed up to now.Method: 108 patients with childhood-onset craniopharyngioma recruited in HIT Endo before 2001 were included in the study. Long-term weight development (BMI SDS after ...

hrp0084p2-519 | Pituitary | ESPE2015

Eating Behaviour, Weight Problems and Eating Disorders in 101 Long-Term Survivors of Childhood-Onset Craniopharyngioma

Hoffmann Anika , Sterkenburg Anthe S , Gebhardt Ursel , Muller Hermann L

Background: As a result of hypothalamic involvement and/or treatment-related hypothalamic damage, up to 75% of childhood craniopharyngioma patients develop hypothalamic obesity.outcome is important for optimization of treatment.Method: Eating behaviour was analysed in 101 survivors of childhood craniopharyngioma, recruited from 1980 to 2001 in the HIT-Endo multicentre study, and in 85 BMI-matched healthy controls using the Inventory for eating behavior a...